Onego Bio

Onego Bio develops Bioalbumen®, an animal-free egg protein created via precision fermentation. This technology replicates ovalbumin, the key protein in egg whites, offering functional equivalence and nutritional benefits without animal agriculture. This process yields a resilient, cost-stable protein source for food manufacturing integration.

Maija Itkonen and Christopher Landowski co-founded Onego Bio in February 2022 as a spin-off. Itkonen, an alternative protein pioneer, and Landowski, a cell agriculture trailblazer, combined their expertise. Their insight leveraged biotechnology to solve environmental and supply chain complexities of conventional egg production, aiming for a sustainable protein future.

Onego Bio serves the food industry, offering manufacturers a functional, sustainable alternative to traditional eggs. Its mission is to provide a superior protein globally, enhancing food system resilience and addressing growing demand for reliable, sustainably produced ingredients. It delivers solutions meeting evolving ethical and environmental standards.

# High-Level Overview

Onego Bio is a Finnish food-biotech company producing Bioalbumen®, a non-animal egg protein created through precision fermentation.[1][2] The company addresses a critical sustainability challenge in global food production by offering a bioidentical alternative to traditional chicken eggs that eliminates environmental, ethical, and safety concerns while maintaining full functional equivalence.

The company serves food manufacturers as an ingredient supplier, targeting the massive industrial egg market—particularly in the U.S., where manufacturers consume approximately one-third of all eggs produced globally.[2] Onego Bio's growth momentum is substantial: the company closed a Series A funding round securing over $40 million in capital in summer 2024[2] and has announced plans to establish a flagship manufacturing facility in Jefferson County, Wisconsin.[5] The company has also filed a GRAS (Generally Recognized as Safe) notice with the FDA to commercialize Bioalbumen® in the United States.[5]

# Origin Story

Onego Bio emerged from groundbreaking research at VTT Technical Research Centre of Finland. In 2016, co-founder Christopher Landowski, a cell agriculture trailblazer who had relocated to Finland from the U.S., began studying *Trichoderma reesei*, a fungus that could be programmed to produce egg protein entirely without animals.[2] This discovery represented a fundamental breakthrough in precision fermentation technology.

The company officially spun out of VTT in 2022 to commercialize this breakthrough.[2] Co-founder Maija Itkonen, an industrial designer and three-time founder with deep experience in food tech, joined Landowski to transform the scientific discovery into a viable business.[2] This combination of scientific expertise and entrepreneurial acumen proved pivotal. The company quickly gained international recognition, winning Fast Company's 2023 World Changing Ideas Award,[1] validating both the technology and its market potential.

# Core Differentiators

• Bioidentical protein production: Bioalbumen® is ovalbumin—the primary protein in egg whites—produced through precision fermentation rather than animal farming, delivering identical nutritional and functional properties.[4]

• Sustainability advantage: Compared to traditional eggs, Bioalbumen® requires 95% less land, generates 72% fewer greenhouse gas emissions, and uses 89% less water.[4]

• Supply chain resilience: The product offers price stability and supply confidence, addressing volatility in traditional egg markets that food manufacturers face.[4]

• Industrial-scale fermentation expertise: The company's roots in VTT's research infrastructure provide deep technical capability in scaling precision fermentation to commercial production levels.[1][3]

• Regulatory progress: Onego Bio has proactively filed GRAS notification with the FDA, positioning itself ahead of competitors in securing U.S. market authorization.[5]

# Role in the Broader Tech Landscape

Onego Bio operates at the intersection of two powerful trends reshaping global food systems: the alternative protein movement and precision fermentation technology. The company is riding the wave of accelerating demand for sustainable protein solutions as traditional animal agriculture faces mounting pressure from climate concerns, resource scarcity, and supply chain fragility.

The timing is particularly favorable. Global protein demand continues rising, yet conventional production methods are increasingly unsustainable.[2] Precision fermentation has matured from laboratory curiosity to industrial viability, with companies like Onego Bio demonstrating that complex proteins can be produced at scale with superior environmental profiles. The company's U.S. expansion—opening San Diego headquarters in 2024 and planning Wisconsin manufacturing—signals that the technology is transitioning from European research to American commercial deployment.

Onego Bio influences the broader ecosystem by validating precision fermentation as a viable pathway for ingredient replacement at industrial scale. Unlike consumer-facing alternative protein companies, Onego Bio's B2B model targets food manufacturers directly, embedding sustainable proteins into existing supply chains rather than requiring consumer behavior change. This approach has broader systemic impact.

# Quick Take & Future Outlook

Onego Bio is positioned to become a critical infrastructure company in the alternative protein ecosystem. The company's next phase centers on manufacturing scale-up and regulatory approval in the U.S. market—the world's largest egg-consuming region. Success in these areas would validate precision fermentation as a commercially viable technology and likely accelerate adoption across other protein categories.

The company's trajectory suggests several key developments ahead: FDA approval of Bioalbumen® will unlock U.S. market entry; the Wisconsin facility will demonstrate manufacturing scalability; and successful partnerships with major food manufacturers will establish market traction. The broader question is whether Onego Bio can achieve cost parity with conventional eggs while maintaining sustainability advantages—the inflection point that determines whether precision fermentation becomes a niche solution or a fundamental restructuring of protein production.